Abstract Library

#4659 Current role of systemic lanreotide therapy of patients with advanced, unresectable, non-metastatic paraganglioma / pheochromocytoma (PPGL) sporadic and hereditary

Introduction: Retrospective, performed in prospective manner single-arm, open-label, case series study to assess the efficacy of lanreotide in patients with unresectable, non-metastatic paraganglioma / pheochromocytoma (PPGL) spontaneous or germline mutations.

Conference:

Presenting Author:

Authors: Kolasińska-Ćwikla A, Pęczkowska M, Michałowska I, Pałucki J, Roszkowska-Purska K,

Keywords: Paraganglioma / pheochromocytoma (PPGL) spontaneous or germline mutations, Lanreotide therapy, fractionated metoxycatecholamines,

#3783 Impact on clinical management of a novel blood-derived liquid biopsy (NETest) in patients with neuroendocrine tumors

Introduction: Despite progresses in NET management, there are persisting challenges regarding initial diagnosis, treatment response assessment and disease follow-up.

Conference:

Presenting Author: Chirindel A

Authors: Chirindel A, de Dosso S, Wild D, Siebenhüner A, Voegeli M,

Keywords: transcriptomics, biomarker, NETest, clinical management, NET,

#3495 PFS evaluation in patients with advanced, non-resectable, progressive GEP-NET treated using combine radioligand/PRRT and CAPTEM therapy

Introduction: Prospective, single-arm, open-label, case series study with assessment the efficacy and safety of combined radioligand therapy (RLT/PRRT) and CAPTEM in advanced, non-resectable progressive GEP-NET (NCT04194125).

Conference:

Presenting Author: Ćwikła J

Authors: Ćwikła J, Kolasińska-Ćwikła A, Zrajkowska A, Nowicka G, Pałucki J,

Keywords: neuroendocrine tumor, combine therapy PRRT and CAPTEM, PFS,

#3404 Defining disease status in gastroenteropancreatic neuroendocrine tumors: Choi criteria or RECIST?

Introduction: Adequate monitoring of changes in tumor load is fundamental for the assessment of disease evolution and response to treatment. There is an ongoing debate on the utility of RECIST v1.1 in gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Conference:

Presenting Author:

Authors: van Treijen M, Schoevers J, Heeres B, van der Zee D, Maas M,

Keywords: treatment response, GEP-NET, imaging, surveillance,

#3402 Serial liquid biopsies - the NETest - in gastroenteropancreatic NET surveillance

Introduction: Current general biomarkers are insufficient to predict the disease course in individual patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs).

Conference:

Presenting Author:

Authors: van Treijen M, Korse C, Verbeek W, Tesselaar M, Valk G,

Keywords: GEP-NET, disease status, prediction, treatment response, surveillance,